These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23772825)

  • 1. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
    Hokland P; Cotter F
    Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
    Feng JH; Xu XJ; Tang YM
    Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring minimal residual disease in pediatric hematologic malignancies.
    Campana D
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
    Freeman SD; Jovanovic JV; Grimwade D
    Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.
    Hokland P; Ommen HB; Nyvold CG; Roug AS
    Br J Haematol; 2012 Sep; 158(5):569-80. PubMed ID: 22738609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches for the detection of minimal residual disease in acute myeloid leukemia.
    van Rhenen A; Moshaver B; Ossenkoppele GJ; Schuurhuis GJ
    Curr Hematol Malig Rep; 2007 May; 2(2):111-8. PubMed ID: 20425359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measurement of minimal residual disease and its implication].
    Tsurusawa M; Hori T
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():731-6. PubMed ID: 23134035
    [No Abstract]   [Full Text] [Related]  

  • 12. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
    Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
    Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug shortages delay cancer clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Jun; 104(12):891-2. PubMed ID: 22715189
    [No Abstract]   [Full Text] [Related]  

  • 16. Is a nadir bone marrow required and, if so, what to do with residual disease?
    Luger SM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
    Jorgensen JL; Chen SS
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
    Drach J; Drach D; Glassl H; Gattringer C; Huber H
    Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.